SEC Form 4 · accession 0000899243-17-027374
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Chandra Vargeese
Officer — See Remarks
Period of report
Nov 22, 2017
Accepted (ET)
Nov 22, 2017 · 9:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Nov 22, 2017 | M | 1,500 | $2.48 | A | 1,500 | D | |
| Ordinary Shares | Nov 22, 2017 | S | 1,500 | $35.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F2 | $2.48 | Nov 22, 2017 | M | 1,500 | D | — | Mar 10, 2025 | Ordinary Shares | 1,500 | 156,542 | D |
Explanation of responses
- F1The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
- F2The incentive share option represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.
Remarks
Senior Vice President, Drug Discovery